Clinical Trials Logo

Secondary Hyperparathyroidism clinical trials

View clinical trials related to Secondary Hyperparathyroidism.

Filter by:

NCT ID: NCT00742716 Completed - Clinical trials for Chronic Kidney Disease

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

Start date: October 2008
Phase: Phase 2
Study type: Interventional

This study will investigate the levels of CTA018 in the body over time (pharmacokinetics, PK) in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis. This study will also investigate the safety and effects of different strengths of CTA018, on parathyroid hormone (PTH) levels.

NCT ID: NCT00701805 Completed - Hemodialysis Clinical Trials

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of paricalcitol injection. Subjects will administer clinical supplies 3 times a week, 40 weeks at dialysis session in dose-titration manner, following 12 weeks of treatment in the dose-response study, M10-309 (NCT00667576).

NCT ID: NCT00667576 Completed - Clinical trials for Secondary Hyperparathyroidism

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

Start date: April 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study was to investigate the initial dose and dose adjustment range for paricalcitol injection in patients with chronic kidney disease on hemodialysis who have secondary hyperparathyroidism.

NCT ID: NCT00601328 Completed - Clinical trials for Secondary Hyperparathyroidism

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions

Start date: July 2003
Phase: N/A
Study type: Interventional

The objective of this study was to assess the bioequivalence of Roxane Laboratories' Calcitriol capsules, 0.25 mcg, to ROCALTROL® capsules, 0.25 mcg (Roche) using a single-dose, 2-treatment, 2-period, crossover design, under fasting conditions

NCT ID: NCT00560300 Completed - Clinical trials for Secondary Hyperparathyroidism

Regulation of Bone Formation in Renal Osteodystrophy

Start date: November 2000
Phase: Phase 2
Study type: Interventional

To examine the effects of two types of active vitamin D (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure

NCT ID: NCT00537979 Completed - Clinical trials for Secondary Hyperparathyroidism

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

Start date: September 2007
Phase: Phase 4
Study type: Interventional

Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis.

NCT ID: NCT00463021 Completed - Clinical trials for Secondary Hyperparathyroidism

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Start date: April 2007
Phase: Phase 4
Study type: Interventional

Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.

NCT ID: NCT00454350 Completed - Clinical trials for Secondary Hyperparathyroidism

A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

Start date: February 2007
Phase: Phase 4
Study type: Interventional

This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).

NCT ID: NCT00431496 Completed - Anemia Clinical Trials

A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to show that the use of cinacalcet in patients with End Stage Renal Disease can help achieve NKF K/DOQI targets for both serum calcium and calcium phosphorous product.

NCT ID: NCT00418600 Completed - Clinical trials for Secondary Hyperparathyroidism

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

Start date: November 2006
Phase: Phase 4
Study type: Interventional

Hectorol is a safe and effective treatment of secondary hyperparathyroidism in hemodialysis patients. Hectorol (doxercalciferol capsules) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and in pre-dialysis patients with Stage 3 or Stage 4 chronic kidney disease. Hectorol (doxercalciferol injection) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. This protocol will determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting subject from Hectorol (doxercalciferol injection.) The study will enroll hemodialysis patients that have been controlled on intravenous Hectorol. the information gained from this study will be a useful guide for physicians in managing CKD Stage 5 patients for whom a change from intravenous to oral vitamin D administration is appropriate.